geneonyxdec202011:start
Differences
This shows you the differences between two versions of the page.
Both sides previous revisionPrevious revisionNext revision | Previous revision | ||
geneonyxdec202011:start [2015/05/06 16:39] – magiero | geneonyxdec202011:start [2015/05/06 18:46] (current) – magiero | ||
---|---|---|---|
Line 26: | Line 26: | ||
• The genetic era now opens up the possibility to utilise a deeper understanding of genetics in a customised, i.e. person-specific, | • The genetic era now opens up the possibility to utilise a deeper understanding of genetics in a customised, i.e. person-specific, | ||
• A single-nucleotide polymorphism (SNP) found in the target //(i.e. molecule to be affected)// of an active ingredient //(i.e. the key molecule in the drug)// provides information on the quality of the expected response\\ | • A single-nucleotide polymorphism (SNP) found in the target //(i.e. molecule to be affected)// of an active ingredient //(i.e. the key molecule in the drug)// provides information on the quality of the expected response\\ | ||
- | • //Use cross-validation | + | • //Use __CROSS-VALIDATION__ |
• This method uses detection of SNP to estimate protein-protein interaction between an ingredient and its direct or indirect target.\\ | • This method uses detection of SNP to estimate protein-protein interaction between an ingredient and its direct or indirect target.\\ | ||
• **As previously discussed**, | • **As previously discussed**, | ||
Line 34: | Line 34: | ||
=== - 1: Identification of ingredients and their biological targets === | === - 1: Identification of ingredients and their biological targets === | ||
- | • | + | • The skin's health is based upon 6 health categories or “pillars”. Each ingredient relates to one or more of these categories.\\ |
+ | • Each ingredient is included in a product in order to take a specific biological pathway in the skin.\\ | ||
+ | • These pathways are: antioxidant pathways for detoxifying, | ||
+ | • The ingredient interacts with its biological target inducing a signalling cascade that is responsive of activation of this pathway, for example as shown in FIG. 2.\\ | ||
+ | • The genes have a proposed or established association with the listed ingredients and efficacy outcomes, but the genetic associations are not limited to the skin. | ||
=== - 2: Identification and selection of a SNP in the ingredient' | === - 2: Identification and selection of a SNP in the ingredient' | ||
+ | |||
+ | {{ fig4.png? | ||
+ | |||
+ | • The ingredient' | ||
+ | • Once the gene is identified, the SNP list for this gene is obtained, for example through NCBI website.\\ | ||
+ | • Calculate SNP impact factor (SIF)\\ | ||
+ | • 5 questions are asked (1: SNP has poor effect on ingredient to 5: SNP has considerable effect on ingredient) to determine SIF.\\ | ||
+ | • A " | ||
+ | |||
+ | ^ ^ | ||
+ | ^ ^ | ||
+ | ^ Ingredient ^ Target | ||
+ | | Niacin | ||
+ | | Collagen | ||
+ | |||
+ | |||
+ | • SNPs are organized into level of interaction with metabolism pathway.\\ | ||
+ | * 1st level: First protein to interact with ingredient (receptor or enzyme responsible for chemical interaction or ingredient modification). | ||
+ | * 2nd level: Key molecule involved in metabolism (e.g. enzyme within metabolic pathway of ingredient). | ||
+ | * 3rd level: Molecule involved in metabolism with minor consequences. | ||
+ | • SNPs that are selected are typically well-represented within the whole population (e.g. greater than 5% frequency within the population).\\ | ||
+ | • However, in some circumstances SNPs may be selected that are very specific to one or more groups within the population (i.e. smaller populations)\\ | ||
+ | • SNPs may be selected that have either a beneficial influence on the metabolism of the ingredient (and therefore its efficacy), or conversely that may have a detrimental influence on the metabolism of the ingredient. | ||
=== - 3: Design of specific primers to amplify the specific SNP associated to ingredients === | === - 3: Design of specific primers to amplify the specific SNP associated to ingredients === | ||
+ | |||
+ | • One of the key aspects of this method is to design specific primers to target the right genotype.\\ | ||
+ | • To amplify DNA, several standard methods can be used such as polymerase chain reaction (PCR), SNAP, or LAPM assay.\\ | ||
+ | • All these techniques are based on the selection of accurate primers.\\ | ||
+ | • Primers were selected according to a number of criteria, including: primer length, the terminal nucleotide in the primer, reasonable GC content and Tm.\\ | ||
=== - 4: Matching ingredients to their target and the associated SNP === | === - 4: Matching ingredients to their target and the associated SNP === | ||
+ | |||
+ | • Each ingredient has the ability to be “metabolised” by a person. This ability is based upon the genetic makeup of this person. \\ | ||
+ | • **The metabolic pathways of many ingredients are identified and a list is created which details those ingredients that either become inactive due to the presence of a SNP, or a highly beneficial ingredient because the SNP creates a failing or fault that is corrected by this ingredient.**\\ | ||
+ | • __Once the ingredients have been matched to their target and the associated SNP__, this information can be entered into a table or database for future reference.\\ | ||
=== - 5: Correlation between ingredients and efficacy associated to SNP === | === - 5: Correlation between ingredients and efficacy associated to SNP === | ||
+ | |||
+ | • It can now be determined if an ingredient is efficient or not when affected by a specific SNP(s) in its target (the aforementioned __CROSS-VALIDATION__? | ||
+ | • The final decision reflects the previously determined efficacy of the ingredient.\\ | ||
+ | • If the target is not functional the ingredient will not be recommended. (i.e. customer' | ||
+ | • In contrast, if the target is not affected by the SNP the ingredient will be recommended (i.e. just a " | ||
+ | • If the SNP provides again enhanced efficacy of an ingredient, the dosage of this ingredient might be considered before being recommended\\ | ||
+ | • taken into consideration is the genotype identified by the test. This will affect the correlation given on the efficacy of the test\\ | ||
=== - 6: Application: | === - 6: Application: | ||
Line 52: | Line 95: | ||
• In this example the cAMP activate the PKA enzyme which releases its catalytic subunits to [[http:// | • In this example the cAMP activate the PKA enzyme which releases its catalytic subunits to [[http:// | ||
• In this case they activate [[http:// | • In this case they activate [[http:// | ||
- | • The presence of FFA in the skin may be very helpful as discussed [[http:// | + | • The presence of FFA in the skin may be very helpful as discussed [[http:// |
• This is a complicated process, but as far as the patent is concerned the key step is to look at potential mutations in the DNA coding for the receptor protein.\\ | • This is a complicated process, but as far as the patent is concerned the key step is to look at potential mutations in the DNA coding for the receptor protein.\\ | ||
- | • In particular genes HM74 (protein GPR109B) and HM74A (GPR109A) code for these proteins with the HM74A apparently coding for a [[http:// | + | • In particular genes HM74 (protein GPR109B) and HM74A (GPR109A) code for these proteins with the HM74A apparently coding for a [[http:// |
- | • If you identify which of these genes is present (or perhaps even some variation on these genes) you can better predict which customer will better | + | • If you identify which of these genes is present (or perhaps even some variation on these genes) you can better predict which customer will better |
==== - Example 2 ==== | ==== - Example 2 ==== |
geneonyxdec202011/start.1430930368.txt.gz · Last modified: 2015/05/06 16:39 by magiero